A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
- Intervention
- Drug: VMD-928 100 mg Tablet · Drug: VMD-928 Tablet and Pembrolizumab (200 mg)